Research & Development

Why Do Brain Diseases Only Target Specific Regions?
Research & Development Why Do Brain Diseases Only Target Specific Regions?

Ivan Kairatov is a leading biopharma expert whose work sits at the intersection of molecular innovation and neurodegenerative research. With years of experience in research and development, he has dedicated his career to untangling the complex web of protein interactions that govern brain health.

How Does the Gut Microbiome Drive Breast Cancer Metastasis?
Research & Development How Does the Gut Microbiome Drive Breast Cancer Metastasis?

The intricate relationship between the trillions of microorganisms residing in the human digestive tract and the progression of malignant tumors has emerged as a cornerstone of modern oncology, shifting focus from purely genetic mutations to systemic microbial health. Recent investigations

Medicare Covers Doctor Visits From Home for Seniors
Research & Development Medicare Covers Doctor Visits From Home for Seniors

Navigating the complexities of modern healthcare management often presents a significant challenge for the senior population, particularly for those facing mobility issues or living in remote rural areas with limited access to specialists. As medical technology continues to advance, a profound

New AMG Pathway Explains Hidden Genetic Causes of Epilepsy
Research & Development New AMG Pathway Explains Hidden Genetic Causes of Epilepsy

The unrelenting rhythm of a neurological storm can dismantle a life in seconds, yet for millions of families, the underlying cause of these recurrent seizures remains a frustratingly silent enigma that modern medicine has struggled to decipher. With approximately 50 million individuals globally

AI Drug Candidates Face a Reality Check in Clinical Trials
Research & Development AI Drug Candidates Face a Reality Check in Clinical Trials

From Digital Blueprints to Biological Realities: The Evolution of Drug Discovery The pharmaceutical industry is currently navigating a pivotal transition where the historical reliance on serendipity and labor-intensive research is being replaced by high-speed, predictive computational models. For

Why Did GSK Scrap Its $2 Billion Chronic Cough Program?
Research & Development Why Did GSK Scrap Its $2 Billion Chronic Cough Program?

Ivan Kairatov has spent decades at the center of biopharmaceutical innovation, specializing in the high-stakes world of respiratory research and development. His expertise in dissecting the clinical and strategic failures of major drug candidates has made him a leading voice for investors and

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later